ABSTRACT
Objective To study the effect of Bairui granule and Deacetylated Ligustrazin injection on plasma BNP and FABP levels in children with heart failure and pneumonia.Methods 60 children of heart failure and pneumonia who received therapy from July 2014 to June 2016 in our hospital were randomly divided into two groups, the observation group and the control group, 30 cases in each group.children in the observation group were treated with sodium phosphate creatine, and the control group was treated with 2-linolenic acid,the clinical outcomes, clinical signs, BNF, FABP, LVEF and LVEDP were compared between the two groups.Results After treatment, the total effective rate of the observation group was significantly higher than that of the control group, the difference was statistically significant (P<0.05); The heart rate, respiratory rate and blood oxygen saturation of the two groups were significantly improved compared with those before treatment ( P<0.05 ) , the heart rate and respiratory rate of the observation group were lower than those of the control group, the oxygen saturation was higher than that of the control group (P<0.05).After treatment, the BNF and FABP indexes of the two groups were lower (P<0.05), and the BNF and FABP indexes in the observation group were lower than those in the control group (P<0.05); The LVEF of the observation group was higher than that of the control group, the LVEDP index was lower than that of the control group, the difference was statistically significant (P<0.05).Conclusion Bairui granule and Deacetylated Ligustrazin injection in the treatment of heart failure with pneumonia has a good effect in the process, which will help reduce the BNP index in children, recovery of children's body function.
ABSTRACT
Objective To investigate the relationship between wheezing and serum levels of 25-hydroxyvitamin D3.Methods 130 children with lower respiratory tract infection were selected as the subjects, the children with wheezing in group A([Abstract] Objective To investigate the relationship between wheezing and serum levels of 25-hydroxyvitamin D3.Methods 130 children with lower respiratory tract infection were selected as the subjects, the children with wheezing in group A(n=70),normal pneumonia (no wheezing) were group B(n=60); The healthy children who were examined in the hospital at the same period were selected as the control group (n=60). The serum levels of 25-hydroxyvitamin D3 were measured by ELISA in the control and hospitalized children. The pathogens and allergens of the two groups were also detected. Results The levels of serum 25-hydroxyvitamin D3 in group A and group B were (56.92±16.88) nmol/L, (70.68±21.96) nmol/L, respectively, which was significantly lower than that in control group (82.69±17.63) nmol/L, ( t=8.50, 3.30,P=0.00,0.00); compared with group A( t=3.85, P=0.00). The positive rate of group A was 65.71%, which was significantly higher than that of group B (35.00%, χ2=12.20,P=0.00). The positive rate of group A was 30.00% compared with the control group (35.00%, χ2=0.36,P=0.54). The serum level of 25-hydroxyvitamin D3 was 75.57% in group A, which was significantly higher than that in group B (60.00%,χ2=14.21, P=0.00). The positive rate of virus detection was 57.14% in 98 children with serum 25-hydroxy vitamin D3 level<75 nmol/L, which was significantly higher than that in serum 25-hydroxy vitamin D3 level≥75 nmol/L(18.75%, χ2=14.25, P=0.00). The positive rate of allergens in serum 25-hydroxy vitamin D3 level <75 nmol/L was 35.71%, which was significantly higher than that in serum 25-hydroxy vitamin D3 level≥75 nmol/L(21.88%, χ2=2.11, P=0.14). Conclusion The main risk factor for children with wheezing is viral infection, while the low level of serum 25-hydroxy vitamin D3 in children increases the risk of viral infection, resulting in increased risk of wheezing in patients,so the clinical can occur through the detection of serum 25- hydroxyvitamin D3 levels to predict and intervention for children with wheezing.